These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35012356)

  • 1. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
    Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
    mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
    Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
    mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Coronavirus Entry
    Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
    mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Fatty Acid Binding Pocket in the SARS-CoV-2 Spike Protein - Confirmed and Potential Ligands.
    Queirós-Reis L; Mesquita JR; Brancale A; Bassetto M
    J Chem Inf Model; 2023 Dec; 63(23):7282-7298. PubMed ID: 37991468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
    Zeng Q; Antia A; Casorla-Perez LA; Puray-Chavez M; Kutluay SB; Ciorba MA; Ding S
    mBio; 2024 Mar; 15(3):e0228723. PubMed ID: 38349185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne.
    Murae M; Sakai S; Miyata N; Shimizu Y; Okemoto-Nakamura Y; Kishimoto T; Ogawa M; Tani H; Tanaka K; Noguchi K; Fukasawa M
    Biol Pharm Bull; 2024; 47(5):930-940. PubMed ID: 38692871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
    Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
    mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.
    Ho HPT; Vo DNK; Lin TY; Hung JN; Chiu YH; Tsai MH
    Biomed Pharmacother; 2022 Nov; 155():113766. PubMed ID: 36271550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
    Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM
    J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
    Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
    mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad Tricyclic Ring Inhibitors Block SARS-CoV-2 Spike Function Required for Viral Entry.
    Ratnapriya S; Braun AR; Cervera Benet H; Carlson D; Ding S; Paulson CN; Mishra N; Sachs JN; Aldrich CC; Finzi A; Herschhorn A
    ACS Infect Dis; 2022 Oct; 8(10):2045-2058. PubMed ID: 36153947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
    Freidel MR; Armen RS
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
    Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
    Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
    Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
    Joseph J; Karthika T; Das VRA; Raj VS
    Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
    Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.